Macrolides, a class of broad-spectrum antibiotics, are gaining attention for their potential in treating parasitic infections due to their favorable safety profiles, pharmacokinetics, and tissue penetration. This study explores the possibility of repurposing macrolides for the treatment of schistosomiasis, a neglected tropical disease caused by the trematode Schistosoma mansoni. Using computational approaches and molecular docking, including quantitative structureactivity relationship (QSAR) models, we evaluated the predicted binding affinities and inhibition probabilities of macrolides against S. mansoni thioredoxin glutathione reductase (SmTGR), a key enzyme in the parasite redox balance. The virtual screening identified eight promising macrolides, with Sorangicin A emerging as a promising hit compound due to its strong predicted interactions with SmTGR. The results suggest that Sorangicin A and other macrolides may exhibit potential antischistosomal activity, highlighting their viability as repurposed therapeutics. This study underscores the value of leveraging established drug classes for new applications, particularly in addressing neglected diseases. Combining QSAR and molecular docking, we demonstrate a cost- and time-efficient strategy for identifying novel treatments. It is offered a pathway to combat schistosomiasis and other parasitic infections, which must be validated experimentally.